CN114578064B - Application of reagent for detecting CAF22 in preparation of composition for evaluating renal tubular injury - Google Patents
Application of reagent for detecting CAF22 in preparation of composition for evaluating renal tubular injury Download PDFInfo
- Publication number
- CN114578064B CN114578064B CN202210483504.8A CN202210483504A CN114578064B CN 114578064 B CN114578064 B CN 114578064B CN 202210483504 A CN202210483504 A CN 202210483504A CN 114578064 B CN114578064 B CN 114578064B
- Authority
- CN
- China
- Prior art keywords
- antibody
- renal tubular
- caf22
- injury
- agrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010024 tubular injury Effects 0.000 title claims abstract description 92
- 208000037978 tubular injury Diseases 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 33
- 210000004900 c-terminal fragment Anatomy 0.000 claims abstract description 32
- 206010061481 Renal injury Diseases 0.000 claims abstract description 23
- 239000003550 marker Substances 0.000 claims abstract description 19
- 238000003745 diagnosis Methods 0.000 claims description 52
- 101150079978 AGRN gene Proteins 0.000 claims description 27
- 102100040026 Agrin Human genes 0.000 claims description 27
- 108700019743 Agrin Proteins 0.000 claims description 27
- 102000013519 Lipocalin-2 Human genes 0.000 claims description 16
- 108010051335 Lipocalin-2 Proteins 0.000 claims description 16
- 210000002700 urine Anatomy 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 13
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims description 12
- 108010090804 Streptavidin Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 102000003810 Interleukin-18 Human genes 0.000 claims description 11
- 108090000171 Interleukin-18 Proteins 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 10
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 claims description 10
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 claims description 10
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 9
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 7
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims description 7
- 239000006249 magnetic particle Substances 0.000 claims description 7
- -1 biotin ester Chemical class 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000004393 prognosis Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 5
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 claims description 4
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 claims description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 3
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000013517 stratification Methods 0.000 claims description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 12
- 239000000090 biomarker Substances 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 10
- 208000037806 kidney injury Diseases 0.000 abstract description 8
- 238000013399 early diagnosis Methods 0.000 abstract description 7
- 102000004405 Collectins Human genes 0.000 abstract description 3
- 108090000909 Collectins Proteins 0.000 abstract description 3
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 27
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 14
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000003908 quality control method Methods 0.000 description 10
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 8
- 238000002038 chemiluminescence detection Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003589 nefrotoxic effect Effects 0.000 description 2
- 231100000381 nephrotoxic Toxicity 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100035484 Neurotrypsin Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 108010037733 neurotrypsin Proteins 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses an application of a detection reagent for a C-terminal fragment (CAF 22) of collectin in preparing a renal tubular injury diagnostic kit and the kit thereof, and provides a new biomarker for diagnosing renal tubular injury by using CAF22 as a diagnostic marker of renal tubular injury; the invention also combines the CAF22 detection with other kidney injury biomarkers, can improve the accuracy and sensitivity of early diagnosis of renal tubular injury, and has higher application value for early diagnosis and treatment of renal injury.
Description
Technical Field
The invention relates to the field of biological diagnosis, in particular to application of a reagent for detecting CAF22 in preparing a composition for evaluating renal tubular injury.
Background
Tubular Injury (renal tubular Injury) is a common complication in critically ill patients and patients undergoing cardiovascular surgery, and has a high incidence and mortality rate, with a postoperative incidence of about 5% to 47% in patients undergoing cardiac surgery and a tubular Injury mortality rate of 50% to 70% in patients with ICU. Tubular injury, if not treated promptly, can progress to chronic kidney disease or require permanent dialysis. Therefore, the early diagnosis and timely intervention and treatment of the renal tubular injury can effectively prevent the further deterioration of the disease and improve the prognosis of patients. In order to improve the diagnosis and treatment level of renal tubular injury and improve the global renal disease prognosis organization (KDIGO), a clinical practice guideline for KDIGO renal tubular injury is published in 2012, and Serum Creatinine (SCR) and urine volume are used as diagnosis and staging standards of renal tubular injury in the guideline. However, both of these indicators have many drawbacks in the diagnosis of renal tubular injury. First, SCr and urine volume are actually biomarkers of renal function and are not markers of renal injury. Second, Scr is a surrogate marker for glomerular filtration rate (GFP), the concentration of which indicates a balance between creatinine production and excretion, but is reflected in an increase in Scr when GFP is less than 50% of the normal level, and thus Scr delays diagnosis of renal tubular injury; third, the SCr is affected by many external factors such as the physiological and pathological states of the patient and the conditions of the drug administration. Fourth, changes in urine volume may not be consistent with the extent of renal injury, for example, patients in dehydration or using diuretics may result in changes in urine volume that are less specific for the diagnosis of renal tubular injury.
The puncture biopsy as the kidney injury diagnosis gold standard has important meanings such as definite diagnosis, treatment guidance, prognosis judgment, pathogenesis discussion, curative effect judgment and mechanism thereof on kidney diseases in specific clinical work, can intuitively and clearly reflect the specific situation of kidney injury through pathological sections, but the current kidney puncture is relatively complex, the pain of a patient is large, and the kidney puncture detection cannot be adopted for the patient to any extent.
The routine items mLB, IgG, TRF, NAG, beta 2-microglobulin can be used as the index of whether the renal function is abnormal or not. However, the failure to reflect a specific renal status and identify the specific cause of renal dysfunction is likely to result in a loss of optimal treatment time due to failure to correctly determine the status of renal injury in the clinic, while intervention at an early stage of renal injury may reduce the mortality associated with renal tubular injury and shorten the treatment time for various types of renal tubular injury, including but not limited to ischemic and nephrotoxic renal injuries. The identification of reliable early biomarkers of renal tubular injury is useful for facilitating early therapeutic intervention and helps guide drug development by providing an indicator of renal toxicity. Therefore, a new biomarker which has good specificity to renal tubular injury, can directly indicate renal tubular injury and can respond in time in early diagnosis is urgently needed.
Disclosure of Invention
In view of the above, the present invention is directed to the use of an agent for detecting C-terminal fragment of Agrin, which is a large proteoglycan, a major heparin sulfate proteoglycan of glomerulus and renal tubular basement membrane, highly expressed in the kidney, for the preparation of a composition for evaluating renal tubular injury in a subject. Agrin is cleaved from the beta site by neurotrypsin, resulting in a 22kDa C-terminal Fragment, i.e.the C-terminal Fragment of Agrin (C-terminal Fragment of Agrin 22, CAF 22). CAF22 is cleared from the circulation primarily by glomerular filtration, and filtered CAF22 is reabsorbed by the proximal tubules. When an injury to renal function occurs, the rate of renal clearance of CAF22 decreases, resulting in elevated levels of CAF22 in the urine. Research finds that the change of CAF22 is in positive correlation with the glomerular filtration rate and the urinary albumin level, so that the invention uses CAF22 as a novel biomarker reflecting the renal tubular injury, and the change of CAF22 is detected to reflect the renal tubular cell injury condition.
In order to achieve the purpose, the invention provides the following technical scheme:
use of a capture agent that detects a C-terminal fragment of agrin in the preparation of a composition for assessing the state of renal tubular injury in a subject.
Preferably, the injury to the renal tubules is selected from ischemic renal injury, nephrotoxic renal injury, or other injury affecting renal tubular cells.
Preferably, the assessing comprises detecting the C-terminal fragment of the polyprotein in a sample of bodily fluid obtained from the subject to provide a detection result, and correlating the detection result with the renal tubular injury status of the subject.
The term "bodily fluid sample" as used herein refers to a bodily fluid sample obtained for the purpose of diagnosis, prognosis, classification or evaluation of the relevant subject, e.g., a patient or transplant donor. In some embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen for a condition. Body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, pleural effusion, and the like. Furthermore, those skilled in the art will appreciate that some bodily fluid samples may be more readily analyzed after fractionation and purification steps, e.g., separation of whole blood into serum or plasma components.
Preferably, the body fluid sample is serum or urine. More preferably, the body fluid sample is a random urine or serum sample prior to renal puncture.
Preferably, the capture agent is an antibody or a derivative thereof that specifically recognizes the C-terminal fragment of agrin.
Preferably, said derivatives comprise a fragment capable of specifically recognizing the C-terminal fragment of agrin: at least one of an antibody functional fragment, an antigen binding fragment, a conjugated antibody, a humanized antibody, a recombinant antibody, a diabody, a chimeric antibody, a monoclonal antibody, a deimmunized antibody, a fully human antibody, a single chain antibody, an Fv fragment, an Fd fragment, an Fab 'fragment, or an F (ab') 2 fragment.
Preferably, wherein the application further comprises:
detecting one or more of the following markers: neutrophil gelatinase-associated lipocalin, interleukin 18, kidney injury molecule-1, liver-type-fatty acid binding protein, metalloproteinase tissue inhibitor 2, insulin-like growth factor binding protein 7;
and assessing the renal tubular injury status of the subject in conjunction with the detection of the C-terminal fragment of the polyprotein.
Preferably, the assessment comprises at least one of a prediction, risk stratification, diagnosis, staging, prognosis or monitoring of the renal tubular injury of the subject.
Preferably, said use comprises detecting the concentration and/or activity of the C-terminal fragment of agrin.
Preferably, said use comprises measuring the concentration and/or activity of at least one of the following markers: neutrophil gelatinase-associated lipocalin, interleukin 18, kidney injury molecule-1, liver-type-fatty acid binding protein, metalloproteinase tissue inhibitor 2, insulin-like growth factor binding protein 7.
Preferably, the composition is an ELISA detection composition, an immunoturbidimetric detection composition, an immunochromatographic detection composition or a chemiluminescent immunoassay detection composition.
Preferably, the composition is a chemiluminescent immunoassay composition comprising a conjugate-labeled agrin C-terminal fragment antibody, a chemiluminescent-label-labeled agrin C-terminal fragment antibody, streptavidin magnetic particles, and a chemiluminescent substrate;
the conjugate label is a biotin ester label;
the chemiluminescence label is one or more of alkaline phosphatase, acridinium ester and derivatives thereof, horseradish peroxidase or ruthenium terpyridyl;
the chemiluminescence zymolyte is one or more of NaOH and H2O2, luminol, (adamantane) -1, 2-dioxyethane or derivatives thereof, APS-5 or tripropylamine.
As a preferable technical scheme of the invention, the working concentration of the C-terminal fragment antibody of the agrin marked by the conjugate is 0.1-2.0 mug/mL; the working concentration of the agrin C-terminal fragment antibody marked by the chemiluminescent marker is 0.1-2.0 mug/mL; the working concentration of the streptavidin magnetic particles is 0.2-2.0 mg/mL, and the particle size is 1.0-5.0 μm.
In a preferred embodiment of the present invention, the antibody against the C-terminal fragment of agrin labeled with the conjugate is stored in a buffer containing NaCl, a protein, a surfactant and a preservative; the agrin C-terminal fragment antibody labeled with the chemiluminescence label is preserved in a buffer solution containing NaCl, protein, a surfactant and a preservative.
More preferably, the buffer component may be PBS, Tris, MES, TBS or HEPES; the surfactant can be one or more of Tween, Brij and Triton; the preservative is one or more of phenol, sodium benzoate, proclin and sodium azide.
In another aspect, the present invention provides a kit comprising the above composition.
As a preferable technical scheme of the invention, the kit also comprises a collectin C-terminal fragment calibrator and a collectin C-terminal fragment quality control product.
In another aspect, the present invention discloses the use of a C-terminal fragment of agrin as a synergistic indicator for assessing the state of renal tubular injury in a subject, the synergistic indicator in combination with a renal injury marker being capable of enhancing the diagnostic effect of the renal injury marker on renal tubular injury, the renal injury marker being a marker capable of indicating renal injury, the assessment comprising detecting the C-terminal fragment of agrin and at least one of the renal injury markers in a sample of bodily fluid obtained from the subject to provide a combined detection result;
and correlating the combined test result with the renal tubular injury status of the subject;
preferably, the kidney injury marker is selected from one or more of the following: NGAL, IL-18, KIM-1, L-FABP, TIMP2 or IGFBP 7.
The synergistic index and the kidney injury marker are combined to improve the diagnosis effect of the kidney injury marker on renal tubular injury, and the effect refers to that: the combination of the C-terminal fragment of the agrin and other kidney status markers can improve the accuracy and sensitivity of other kidney injury markers to renal tubular injury detection.
The term "subject" as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are useful for human and veterinary disease. Further, the present invention may also be used for post mortem analysis when the subject is preferably a living organism. Preferably the subject is a human, and most preferably is a "patient", as used herein refers to a living human receiving medical care for a disease or condition. This includes persons without established disease who are being examined for pathological phenomena. Preferably, the subject is selected from patients with abnormal renal status.
The term "diagnosis" as used herein refers to a method by which one of skill in the art can estimate and/or determine the likelihood of whether a patient has a given disease or condition, as an aid to diagnosis. In the context of the present invention, "diagnosis" includes the use of the results of detection, most preferably immunodetection, of the kidney injury markers used in the present invention, optionally together with other clinical features, to obtain samples and tests from a patient to achieve a diagnosis (i.e., the occurrence or non-occurrence) of a renal tubular injury. Such a diagnosis is "determined", which is not meant to imply that the diagnosis is 100% accurate. Thus, a measured level of a biomarker on one side of the predetermined diagnostic threshold indicates a greater likelihood of the subject developing a disease relative to a measured level on the other side of the predetermined diagnostic threshold.
Similarly, prognostic risk represents the likelihood that a given process or outcome will occur. A change in the level or level of a prognostic indicator, which in turn is associated with an increased likelihood of disease (e.g., renal tubular injury will occur), refers to "indicating an increased likelihood" of an adverse outcome in a patient.
The term "antibody" as used herein refers to a peptide or polypeptide derived from substantially an immunoglobulin based on coding or post-immunoglobulin gene simulation or immunoglobulin genes or fragments thereof, capable of specifically binding an antigen or epitope.
The invention has the beneficial effects that: the invention takes the CAF22 as a diagnosis marker of the renal tubular injury, provides a new biomarker for the diagnosis of the renal tubular injury, can reflect the integrity of a proximal tubule, and has higher application value in the aspect of early diagnosis or dynamic detection of the renal tubular injury. And the invention is based on CAF22 combined with other biomarkers, which can further improve the sensitivity and accuracy of detection and provide more possibilities for diagnosis. In clinical treatment, once an indicator of tubular cell injury or acute renal failure is detected, intervention and treatment of the disease or condition is initiated, and the clinician can monitor the course of the treatment or intervention using the methods and kits of the invention. Typically, when treatment of renal injury begins and continues, one or more subsequent post-treatment urine samples are obtained and analyzed for the presence of biomarkers. The degree of improvement can be expressed as a corresponding decrease in the measured level of CAF22 in the sample.
Therefore, the CAF22 can be combined with other renal tubular injury biomarkers to be used for diagnosing the renal tubular injury, can improve the sensitivity and accuracy of detection, and has important significance for early diagnosis or dynamic detection of the renal tubular injury.
Drawings
In order to make the object, technical scheme and beneficial effect of the invention more clear, the invention provides the following drawings for explanation:
FIG. 1 is a CAF22 kit dilution line;
FIG. 2 is a renal tubular injury grading;
FIG. 3 is a ROC curve for CAF22 diagnosis of renal tubular injury;
FIG. 4A is a ROC curve for diagnosis of renal tubular injury by NGAL;
FIG. 4B is a ROC curve for CAF22 in combination with NGAL for the diagnosis of renal tubular injury;
FIG. 5A is a ROC curve for TIMP2 diagnosis of renal tubular injury;
FIG. 5B is a ROC curve of KIM-1 for diagnosis of renal tubular injury;
FIG. 5C is a ROC curve for CAF22 in combination with TIMP2 and KIM-1 for diagnosis of renal tubular injury;
FIG. 6A is a ROC curve for L-FABP diagnosis of renal tubular injury;
FIG. 6B is a ROC curve for CAF22 in combination with NGAL, L-FABP and TIMP2 for the diagnosis of renal tubular injury;
FIG. 7A is a ROC curve for diagnosis of renal tubular injury by IGFBP 7;
FIG. 7B is a ROC curve for IL-18 diagnosis of renal tubular injury;
FIG. 7C is a ROC curve for CAF22 in combination with IGFBP7 and IL-18 for diagnosis of renal tubular injury;
FIG. 7D is a ROC curve for CAF22 in combination with IGFBP7 and IL-18 for diagnosis of renal tubular injury;
FIG. 8 is a ROC curve for diagnosis of renal tubular injury using TIMP2 in combination with IGFBP 7;
FIG. 9 is a ROC curve for diagnosis of urinary albumin on renal tubular injury;
FIG. 10 is a ROC curve for urine IgG diagnostic of renal tubular injury;
FIG. 11 is a ROC curve for the diagnosis of renal tubular injury by urinary NAG;
FIG. 12 is a ROC curve for the diagnosis of renal tubular injury from urinary TRF;
FIG. 13 is a ROC curve for urinary α MG diagnosis of renal tubular injury;
FIG. 14 is a ROC curve for renal function markers and renal tubular injury diagnosis.
Detailed Description
The present invention is further described with reference to the following drawings and specific examples so that those skilled in the art can better understand the present invention and can practice the present invention, but the examples are not intended to limit the present invention.
Example 1: sample collection
A total of 157 urine samples with abnormal renal status were collected.
The abnormal renal status is represented by: the indexes of albumin, immunoglobulin G, transferrin, alpha 1 microglobulin, lysosome enzyme and creatinine in urine are abnormal.
Example 2 preparation method of CAF22 chemiluminescence detection kit
The CAF22 chemiluminescence detection kit mainly comprises a CAF22 antibody marked by a conjugate, a CAF22 antibody marked by a chemiluminescence marker, streptavidin magnetic particles, a chemiluminescence substrate, a CAF22 standard substance and a quality control substance.
The preparation method of the CAF22 chemiluminescence detection kit mainly comprises the following steps:
step 1) preparation of conjugate-labeled CAF22 antibody
Adding an activating agent biotin ester into the desalted CAF22 antibody according to the molar ratio of 1:10, uniformly mixing, and reacting for 4 hours at room temperature in a dark place. And adding the solution after reaction into a pre-wetted PD-10 purification column for purification. The purified conjugate was assayed for concentration using A280 and stored at-20 ℃ after addition of an equal volume of glycerol. When used, the reagent was diluted to a concentration of 0.1 to 2.0. mu.g/mL with a buffer solution containing 50 mM PBS (pH 7.4), 0.15M NaCl, 1g/L bovine serum albumin, 5g/L Tween 20, and 0.1% by mass sodium azide, and the solution was used as R1.
In this step, the Biotin ester label may be Sulfo-NHS-Biotin, Sulfo-NHS-LC-Biotin; preferably, the Biotin ester marker is Sulfo-NHS-LC-LC-Biotin; PBS can be replaced by one of Tris, MES, TBS and HEPES; tween 20 can be one or more of other Tween, Brij, and Triton; sodium azide may be used with one or more combinations of other preservatives such as phenol, sodium benzoate and proclin.
Step 2) preparation of chemiluminescent marker labeled CAF22 antibody
And (3) activating the desalted CAF22 antibody by using 2-IT according to the molar ratio of 1:5, and desalting the activated CAF22 antibody by using a G-25 column. Alkaline phosphatase was activated with Sulfo-SMCC at a molar ratio of 1:20, and the activated CAF22 antibody was desalted by passing through a G-25 column. The activated CAF22 antibody and the activated alkaline phosphatase were mixed well, and the mixture was left to stand still at 4 ℃ for 24 hours, and the alkaline phosphatase-labeled antibody was purified by AKTA PRIME system. The purified alkaline phosphatase label was diluted to a concentration of 0.01 to 2.0. mu.g/mL with a buffer solution containing 50 mM pH 7.4 PBS, 0.1% casein, 0.05% Tween 20, and 0.1% sodium azide, and used as R2.
In this step, the alkaline phosphatase may also be replaced with other chemiluminescent markers, such as one or more of acridinium ester and its derivatives, horseradish peroxidase or ruthenium terpyridyl; PBS can be replaced by one of Tris, MES, TBS and HEPES; tween 20 can be one or more of other Tween, Brij, and Triton; sodium azide may use one or more combinations of other preservatives such as phenol, sodium benzoate and proclin.
Step 3) preparation of streptavidin magnetic particles
The magnetic particles of high-concentration streptavidin are diluted to 0.2-2.0 mu g/mL by magnetic bead diluent, the magnetic bead diluent contains buffer solution of 50 mM pH 7.4 PBS, 0.1% bovine serum albumin, 0.05% Tween 20 and 0.1% sodium azide, and the particle size of the magnetic bead is 1.0-5.0 mu m.
Step 4) preparation of a chemiluminescent substrate
In this step, the substrate of the chemiluminescent detection kit may be NaOH or H 2 O 2 One or more of luminol, 1, 2-dioxyethane (adamantane) -1, 2-dioxyethane or derivatives thereof, APS-5 or tripropylamine.
Step 4) kit Assembly
And respectively filling the diluted conjugate labeled CAF22 antibody, the diluted chemiluminescent label labeled CAF22 antibody, streptavidin magnetic particles, a chemiluminescent substrate, a CAF22 calibrator and a quality control product into a kit matched with a full-automatic chemiluminescent immunoassay analyzer to form the CAF22 chemiluminescent detection kit.
Calibration products: recombinant CAF22 protein was diluted to 1000.0 ng/mL, 800.0 ng/mL, 400.0 ng/mL, 200.0 ng/mL, 100.0 ng/mL, 50.0 ng/mL, 10.0 ng/mL, 0.0 ng/mL with 20 mM PBS buffer pH 7.4 containing a mass fraction of 1% BSA.
Quality control product: recombinant CAF22 protein was diluted to 100.0 ng/mL and 500.0 ng/mL with 20 mM PBS buffer pH 7.4 containing 1% BSA.
Example 4 method of detecting CAF22 with CAF22 chemiluminescence detection kit
The chemiluminescence detection kit for detecting CAF22 comprises a reagent R1, a reagent R2, streptavidin magnetic beads, a chemiluminescence substrate, a CAF22 calibrator and a quality control product.
R1 is biotin-conjugated CAF22 antibody, stored in 50 mM PBS pH 7.4 and 0.15M NaCl, and buffer solution also contains mass fraction of 0.1% sodium azide, 0.5 g/L Tween 20 and 1g/L bovine serum albumin.
R2 is alkaline phosphatase-labeled CAF22 antibody, stored in 0.05M PBS and 0.15M NaCl, and further containing 0.1% sodium azide, 0.5 g/L Tween 20 and 1g/L sodium caseinate in the buffer.
The concentration of streptavidin magnetic beads is 1 mg/mL, and the particle size of the magnetic beads is 2.8 mu M.
The chemiluminescent substrate is APS-5.
Taking a full-automatic chemiluminescence immunoassay analyzer as a detection tool, taking a detection mode as a sandwich method, adding 5 muL of a test sample or a calibrator or a quality control product, 50 muL of a biotin-labeled CAF22 antibody and 50 muL of a basic phosphatase-labeled CAF22 antibody into a reaction cup of the analyzer, feeding the mixed solution into an incubation disc, and incubating for 10min at 37 ℃; then adding 30 mu L of streptavidin coated magnetic beads, uniformly mixing, sending into an incubation disc, and carrying out magnetic separation after incubating for 5min at 37 ℃; and adding 200 mu L of luminescent substrate APS-5 into the mixture, and fully mixing uniformly to test a luminescence value after reaction.
In this example, the working concentration of the biotin-labeled CAF22 antibody was 1. mu.g/mL, the working concentration of the alkaline phosphatase-labeled CAF22 antibody was 0.05. mu.g/mL, and the working concentration of the streptavidin-coated magnetic beads was 1 mg/mL for detection.
Example 5 CAF22 chemiluminescence detection kit basic Properties
(1) CAF22 kit sensitivity
Calibrators (CALA) at 0ng/mL were tested 20 times with the CAF22 kit, the mean and standard deviation were calculated, and adjacent Calibrators (CALB) were tested, with the results shown in Table 1. The A, B light values are regressed at two points to obtain an equation. The mean value of CAL A plus two standard deviations is substituted into the regression equation, and the corresponding concentration value is the sensitivity.
By test and calculation, the sensitivity of the CAF22 chemiluminescence detection kit is 0.3 ng/mL.
(2) CAF22 kit Linearity
Diluting a sample with the concentration of 1000 ng/mL by using a sample diluent according to the dilution proportion of 1/1, 3/4, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and 1/128 respectively, testing the diluted sample by using a CAF22 kit, recording the test concentration and the corresponding dilution proportion of the sample, wherein the CAF22 kit dilution linearity is shown in figure 1, and the result shows that the calibration curve R is between 7.75 ng/mL and 500 ng/mL 2 >0.99。
(3) CAF22 kit repeatability
The mean and coefficient of variation were calculated for 10 samples at 92 ng/mL and 642 ng/mL, respectively, and the results are shown in Table 2.
The results show that the intra-batch-CV of sample 1 and sample 2 are 2.62% and 2.39%, respectively, indicating that the stability of the kit of the present invention is good.
Example 6 use of the CAF22 test kit comprised by the invention in the early diagnosis of renal tubular injury
The sample of this example is the sample of example 1.
The CAF22 chemiluminescence detection kit comprises the following detection steps of a body fluid sample of a patient:
step 1): sample collection and processing: collecting urine of a patient, centrifuging at 3000 rpm for 10min, transferring supernatant into a centrifuge tube, and storing the treated urine sample at 4 ℃ for no more than one week or at-20 ℃ without repeated freeze thawing.
Step 2): as an example, the kit adopts the case that R1 is biotin-labeled CAF22 antibody, R2 is alkaline phosphatase-labeled antibody, and the magnetic beads are streptavidin-coated magnetic beads.
Step 3): calibration, the kit and CAF22 master curve barcode were scanned on a fully automated chemiluminescent immunoassay analyzer, the calibrator was placed at the sample site, and the instrument could then calibrate the CAF22 project.
Step 4): and (4) quality control, namely detecting the light value of a quality control product on an instrument, automatically calculating the concentration through the standard curve, if the concentration of the quality control product is within the identification range, passing the test, otherwise, testing again, and testing the sample after the quality control is qualified.
And step 5): and (3) sample testing, namely putting a urine sample in a sample position, measuring the light value by using the instrument, automatically calculating the concentration by using a standard curve, and judging the result according to the detection concentration and the reference range.
Grading the result obtained by pathological biopsy according to the grading standard:
degree of renal tubular injury: 1-no denaturation; 2-denaturation; 3-brush edge drop and/or flattening; 4-naked membrane and/or necrosis
Area of renal tubular injury (cumulative degree of injury): 1-small oven; 2-a local range; 3-multiple cooking ranges; 4-Dispersion
The grading standard corresponds to the detection result.
The results of the grading are shown in FIG. 2;
and (3) drawing an ROC curve according to the detection result, (wherein the drawing tool is medcalc, the detection result of the kit of the sample and the pathological detection standard of the renal tubular injury are used as comparison, and the software can calculate the threshold value of the renal tubular injury degree and compare the threshold value with the threshold value, so that the renal tubular injury can be predicted, risk graded, diagnosed, staged, prognosed, classified and monitored according to the detection result).
As shown in fig. 3, the area under the curve (AUC) was calculated to be 0.916 with 95% confidence intervals of 0.8871-0.9549. When AUC is greater than 0.5, the prediction method is effective, and the prediction method is very effective, so that the CAF22 has good specificity and sensitivity for diagnosing the renal tubular injury, and has higher use value and diagnostic value clinically.
Example 7 marker combination assay
This example mainly illustrates that the sensitivity of detection can be further improved by combining CAF22 with other renal function indicators for detection.
(a) CAF22 in combination with NGAL
ROC curves were plotted for NGAL concentration versus renal tubular injury diagnosis and for NGAL in combination with CAF22 versus renal tubular injury diagnosis, and the results are shown in fig. 4A and 4B. The results show that the AUC for NGAL diagnosis of renal tubular injury is 0.8048; AUC increased to 0.934 after NGAL in combination with CAF 22. The result shows that the effectiveness of diagnosing the renal tubular injury is improved by combining the index CAF 22.
(b) CAF22 combined with TIMP2 and KIM-1
The results are shown in fig. 5A, 5B, and 5C, and show that TIMP2 has an AUC of 0.7721 for the diagnosis of renal tubular injury; the AUC of KIM-1 for the diagnosis of renal tubular injury was 0.7267; the ROC of CAF22 in combination with TIMP2, KIM-1 increased to 0.947.
(c) CAF22 in combination with NGAL, L-FABP, TIMP2
The results are shown in fig. 5A, 4A, 6A, and 6B, and show that TIMP2 has an AUC of 0.7721 for the diagnosis of renal tubular injury; AUC for diagnosis of renal tubular injury by NGAL is 0.8048; AUC of L-FABP for diagnosis of renal tubular injury was 0.8264; the AUC of CAF22 in combination with NGAL, L-FABP, TIMP2 increased to 0.948.
(d) CAF22 combined with IGFBP7 and IL-18
The results are shown in fig. 7A, 7B, 7C, and 7D, and show that AUC of IGFBP7 for renal tubular injury diagnosis is 0.6138; the AUC of IL-18 in the diagnosis of tubular injury was 0.6229, and the AUC of CAF22 in combination with IGFBP7 and IL-18 increased to 0.935.
(e) TIMP2 in combination with IGFBP7
The results are shown in fig. 7A, 5A and 8, and show that AUC of IGFBP7 for renal tubular injury diagnosis is 0.6138, and AUC of TIMP2 for renal tubular injury diagnosis is 0.7721; the AUC for diagnosis of renal tubular injury by IGFBP7 in combination with TIMP2 was 0.7365.
The combination of the (a) - (e) shows that the combination of other indexes with common effects with CAF22 can obviously improve the sensitivity for detecting the renal tubular injury, and the combination of other indexes with common effects cannot improve the sensitivity for detecting the renal tubular injury. In addition, differences exist between different indexes combined by the CAF22, the sensitivity is higher when the number of the indexes which are not combined is larger, a complex calculation relation exists, and compared with a single index of the CAF22, the detection accuracy can be further improved by combining other indexes.
Example 8 correlation of routine markers for detecting renal tubular injury
To prove that the renal function marker can not be used as a renal tubular injury marker or a renal tubular cell injury marker, ROC curves are drawn by using the conventional renal function indexes of mALB, IgG, TRF, NAG and beta 2-microglobulin and the renal tubular injury, and the results are shown in fig. 9-14. The results show that the relevance of mLB, IgG, TRF, NAG and beta 2-microglobulin is lower than 0.8, and some indexes are even only about 0.6, and the relevance is not high.
The correlation of CAF22 of the present invention is best compared to these conventional indicators and can be effectively used to indicate and diagnose the status of renal tubular injury.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Claims (10)
1. Use of a capture agent that detects a C-terminal fragment of agrin for the preparation of a composition for assessing the state of renal tubular injury in a subject, said assessment being detection of a C-terminal fragment of agrin, renal injury molecule-1 and tissue inhibitor of metalloprotease 2;
or detecting agrin C-terminal fragment, neutrophil gelatinase-associated lipocalin, metalloproteinase tissue inhibitor 2, and liver-type-fatty acid binding protein;
or detecting agrin C-terminal fragment, insulin-like growth factor binding protein 7 and interleukin 18.
2. The use of claim 1, wherein the assessment comprises detecting the C-terminal fragment of agrin in a sample of bodily fluid obtained from the subject to provide a test result, and correlating the test result with the renal tubular injury status of the subject.
3. The use of claim 1, wherein said capture agent is an antibody or derivative thereof that specifically recognizes a C-terminal fragment of agrin.
4. Use according to claim 3, wherein said derivative comprises at least one of an antibody functional fragment, an antigen-binding fragment, a conjugated antibody, a humanized antibody, a recombinant antibody, a diabody, a chimeric antibody, a monoclonal antibody, a deimmunized antibody, a fully human antibody, a single-chain antibody, an Fv fragment, an Fd fragment, an Fab 'fragment or an F (ab') 2 fragment, capable of specifically recognizing the C-terminal fragment of agrin.
5. The use of any one of claims 1-4, wherein the assessment comprises at least one of a prediction, risk stratification, diagnosis, staging, prognosis or monitoring of the renal tubular injury in the subject.
6. Use according to any one of claims 1 to 4, wherein the use comprises detecting the concentration and/or activity of the C-terminal fragment of agrin.
7. Use according to claim 1, comprising measuring the concentration and/or activity of at least one of the following markers: neutrophil gelatinase-associated lipocalin, interleukin 18, kidney injury molecule-1, liver-type-fatty acid binding protein, metalloproteinase tissue inhibitor 2, insulin-like growth factor binding protein 7.
8. Use according to claim 2, wherein the body fluid sample is serum or urine.
9. The use according to any one of claims 1 to 4, 7 or 8, wherein the composition is an ELISA, immunoturbidimetric assay, immunochromatographic assay or chemiluminescent immunoassay.
10. The use of claim 9, wherein the composition is a chemiluminescent immunoassay composition comprising a conjugate-labeled agrin C-terminal fragment antibody, a chemiluminescent label-labeled agrin C-terminal fragment antibody, streptavidin magnetic particles, and a chemiluminescent substrate;
the conjugate label is a biotin ester label;
the chemiluminescent marker is one or more of alkaline phosphatase, acridinium ester and derivatives thereof, horseradish peroxidase or ruthenium terpyridyl;
the chemiluminescent substrate is NaOH and H 2 O 2 One or more of luminol, adamantane-1, 2-dioxyethane or derivatives thereof, APS-5 or tripropylamine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210483504.8A CN114578064B (en) | 2022-05-05 | 2022-05-05 | Application of reagent for detecting CAF22 in preparation of composition for evaluating renal tubular injury |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210483504.8A CN114578064B (en) | 2022-05-05 | 2022-05-05 | Application of reagent for detecting CAF22 in preparation of composition for evaluating renal tubular injury |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114578064A CN114578064A (en) | 2022-06-03 |
CN114578064B true CN114578064B (en) | 2022-08-16 |
Family
ID=81779200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210483504.8A Active CN114578064B (en) | 2022-05-05 | 2022-05-05 | Application of reagent for detecting CAF22 in preparation of composition for evaluating renal tubular injury |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114578064B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
CN107703123A (en) * | 2017-09-15 | 2018-02-16 | 江苏浩欧博生物医药股份有限公司 | A kind of chemical luminescent analysis reagent kid of serum tryptase and preparation method thereof and detection method |
CN113804896A (en) * | 2021-09-14 | 2021-12-17 | 北京利德曼生化股份有限公司 | Magnetic particle chemiluminescence kit for measuring interleukin-8 content in human serum |
-
2022
- 2022-05-05 CN CN202210483504.8A patent/CN114578064B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114578064A (en) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101960308B (en) | Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker | |
JP5931200B2 (en) | Diagnosis of renal injury after acute event or surgical intervention based on L-FABP | |
CA2748937C (en) | Urine and serum biomarkers associated with diabetic nephropathy | |
CN103403554A (en) | Methods of prognosis and diagnosis in chronic heart failure | |
JP6639392B2 (en) | Method for selective measurement of placental growth factor 2 | |
US8313919B2 (en) | Diagnostic test for renal injury | |
JP2011530705A (en) | D-dimer for pulmonary embolism, troponin, NT-proBNP | |
AU2017232081A1 (en) | Acute kidney injury | |
EP2442105A1 (en) | Test method on renal diseases | |
US20100233740A1 (en) | Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis | |
US20140120174A1 (en) | Methods of prognosis and diagnosis of sepsis | |
US20040241774A1 (en) | Kits for diagnosing kidney diseases | |
EP3225996B1 (en) | Method for assisting diagnosis of risk of progression to nephropathy and use of reagent kit | |
KR20180117649A (en) | IGFBP-7 as a marker of preeclampsia | |
CN114578064B (en) | Application of reagent for detecting CAF22 in preparation of composition for evaluating renal tubular injury | |
CN114814238A (en) | Application of CAF22 detection reagent in preparation of AKI diagnostic composition | |
US20160025737A1 (en) | Biomarkers for assessment of preeclampsia | |
US20060166272A1 (en) | Method of adjudicating on acute aortic dissection and reagent for adjudication | |
US20240302385A1 (en) | Biomarker for detecting tubulointerstitial disorder and use thereof | |
CN210514336U (en) | Combined quantitative detection kit for five cardiac markers | |
JP2011521254A (en) | Total plasma FVII / FVIIA levels as an indicator of female preeclampsia during pregnancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231008 Address after: 400084 floors 1-4, building 30, No. 6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing Patentee after: Zhongyuan Huiji Biotechnology Co.,Ltd. Address before: Room 07, Block E, 101 / F, building 24, No.68 courtyard, Beiqing Road, Haidian District, Beijing Patentee before: Beijing Watson saiser Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |